On this page
Fragile X syndrome (FXS) is an FMR1-related neurodevelopmental condition. It is usually caused by a full-mutation CGG repeat expansion in FMR1, with abnormal methylation and reduced or absent FMRP. The developmental, learning, behavioral, communication, and medical profile varies widely in all genders.[1]
Coding
- ICD-10-CM (United States):
Q99.2— Fragile X chromosome.[2]
Confirm current coding and payer requirements in the relevant setting. A billing code does not establish the molecular diagnosis.
Clinical Profile
FXS can involve developmental delay or intellectual disability, speech and language delay, attention differences, anxiety, sensory sensitivities, autistic features, and challenges with emotional or behavioral regulation. Seizures, sleep problems, recurrent otitis media, strabismus, reflux, joint laxity, flat feet, and mitral valve prolapse or aortic-root dilation can occur. Physical features may be subtle or absent, especially in young children.[1]
Males with a full mutation are often more affected, but sex does not determine an individual's abilities or support needs. Females can have clinically significant learning, communication, anxiety, attention, or adaptive needs.[1]
Diagnosis
Diagnosis is established with specialized molecular testing that measures the FMR1 CGG repeat and assesses methylation when indicated. Typical multigene panels, exome sequencing, and standard chromosome analysis do not reliably rule out FXS. Genetic counseling helps interpret full mutations, premutations, mosaic results, inheritance, and implications for relatives.[1]
Developmental or behavioral features alone are not specific to FXS. Evaluation should also identify co-occurring conditions and the person's strengths across cognition, adaptive skills, language, motor function, hearing, vision, sleep, feeding, and mental health.[1]
Medical and Developmental Management
There is no single treatment that addresses all features of FXS. Care is individualized and may combine developmental and educational services, speech-language and occupational therapy, behavioral or psychological support, and standard treatment of co-occurring medical conditions.[1]
Medication decisions target a defined symptom such as attention difficulty, anxiety, severe irritability, sleep disturbance, or seizures. Selection, dosing, monitoring, and review belong with an experienced prescriber; a diagnosis alone is not an indication for a specific medicine.[1]
Ongoing care commonly reviews hearing and middle-ear disease, vision, dental health, growth and nutrition, sleep-disordered breathing, reflux, seizures, musculoskeletal concerns, cardiovascular findings, mental health, and family support. Frequency depends on age, findings, and the treating team's plan.[1]
Communication
Communication profiles range from fluent speech to very limited speech. Assessment should consider receptive and expressive language, speech intelligibility, social communication, anxiety and arousal, sensory regulation, hearing, motor access, literacy, and communication across home, school, work, healthcare, and community settings.[1]
Use the person's strongest communication modes together: speech, gesture, sign, writing, pictures, objects, low-tech boards, or speech-generating technology. If speech is very delayed or does not meet everyday needs, GeneReviews recommends evaluation for alternative communication by an SLP with AAC expertise. AAC does not require a person to demonstrate a particular cognitive, symbolic, or motor prerequisite.[1,3]
FXS does not by itself prescribe touch access, symbols, eye gaze, or switch scanning. Feature matching should be based on direct trials and the individual's language, vision, hearing, motor control, sensory preferences, environments, communication partners, and goals. Provide a reliable way to communicate refusal, pain, distress, and the need for a break. The general evaluation, trial, funding, and acquisition process is described in AAC Device Acquisition.[3]
Communication partners can reduce pressure by allowing processing time, using clear language, preparing for transitions, and recognizing that reduced eye contact or dysregulated speech does not mean the person has nothing to say.
Feeding and Swallowing
Feeding support should respond to observed concerns rather than routine diagnosis-based oral-motor exercises. Refer for feeding or swallowing assessment when there is coughing or choking, recurrent respiratory illness, prolonged or highly restricted meals, pain, poor growth, dehydration, or a change in eating safety. Medical, gastrointestinal, dental, sensory, and behavioral contributors may overlap and should be considered together.[1]
Education and Participation
Early intervention and individualized educational planning may address language, learning, motor, sensory, adaptive, and social-emotional goals. Supports should be based on assessment and participation needs, not assumptions about a Fragile X learning style. Predictability, visual or written supports, smaller instructional steps, regulation breaks, and accessible communication may help some learners but require individual testing and review.[1]
Include the person in goal setting and transition planning. Preserve access to age-respectful vocabulary, literacy instruction, relationships, self-advocacy, and communication about health and safety.
Urgent Boundaries
Follow an established seizure plan and seek emergency help for a prolonged seizure, repeated seizures without recovery, breathing difficulty, or serious injury. New choking with respiratory distress, signs of aspiration, abrupt loss of skills, severe self-injury, or an immediate mental-health safety concern requires prompt professional assessment. Local emergency guidance takes priority over this page.
Support
References
- Hunter JE, Berry-Kravis E, Hipp H, Todd PK. FMR1 Disorders. GeneReviews. Updated May 16, 2024.
- Centers for Medicare & Medicaid Services. FY 2026 ICD-10-CM definitions: Q99.2 Fragile X chromosome.
- American Speech-Language-Hearing Association. Augmentative and Alternative Communication Practice Portal. Accessed July 21, 2026.